Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

<p>Abstract</p> <p>Background</p> <p>Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, n...

Full description

Bibliographic Details
Main Authors: Fabi Alessandra, Russillo Michelangelo, Ferretti Gianluigi, Metro Giulio, Nisticò Cecilia, Papaldo Paola, De Vita Ferdinando, D’Auria Giuliana, Vidiri Antonello, Giannarelli Diana, Cognetti Francesco
Format: Article
Language:English
Published: BMC 2012-10-01
Series:BMC Cancer
Subjects:
Maintenance Bevacizumab
Antiangiogenic agents
HER2 negative metastatic breast cancer
Online Access:http://www.biomedcentral.com/1471-2407/12/482

Similar Items

Similar Items